Voyage AI Innovations Inc.
Total Consideration
$160.9M
Share price: $292.05
Purchase-Price Allocation
Goodwill
$121.7M
Deferred Tax Liability
$2.7M
MONGODB, INC. — Key Metrics
3 years of history · ending 2026-01-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-1
Book Value Per Share
$36
Free Cash Flow Per Share
$6
Cash Per Share
$13
Revenue Per Share
$30
OCF Per Share
$6
Return on Equity
-2.5%
Return on Assets
-2.0%
Return on Invested Capital
-3.8%
Debt to Equity
—
Current Ratio
4.65
Quick Ratio
4.65
Asset Turnover
0.69
Days Sales Outstanding
73.92
Days Payables Outstanding
10.63
R&D / Revenue
29.1%
SBC / Revenue
22.3%
Capex / Revenue
0.2%
Working Capital
$2.45B
Net Current Asset Value
$2.31B
Invested Capital
$2.95B
OCF / Net Income
-7.10
FCF / Net Income
-7.03
Accruals Ratio (Sloan)
-15.3%
Net Debt
$-1.08B
Net Debt / EBITDA
9.46
Interest Coverage
-43.79
Cash Coverage
161.49
Capex Coverage
101.84
Tangible Common Equity
$2.73B
TCE / Total Assets
72.5%
Goodwill / Total Assets
5.1%
NOPAT
$-108M
Cash ROIC
17.4%
WC / Revenue
99.3%
Capex / D&A
0.22
Reinvestment Rate
11.2%
Total Payout Ratio
-562.7%
Asset Growth vs Revenue Growth
-13.2%
Revenue 5Y CAGR
33.1%
Book Value 5Y CAGR
101.9%
Stock Price (FY-end)
$371
Market Cap
$30.17B
P/S Ratio
12.25
P/B Ratio
10.22
P/TB Ratio
11.07
P/OCF Ratio
59.72
P/FCF Ratio
60.32
Enterprise Value
$29.09B
EV / Sales
11.81
EV / FCF
58.15
FCF Yield
1.7%
Shareholder Yield
-0.5%
Buyback Yield
1.3%
R&D Yield
2.4%
Capex Yield
0.0%
Shares Variation (YoY)
9.0%
Beta (5Y)
2.07
Cost of Equity
14.8%
Cost of Debt (after tax)
—
52W High
$441
52W Low
$146
Trailing Return 1Y
33.4%
Trailing Return 5Y
0.6%
F-Score (Piotroski)
4.00
Z-Score (Altman)
23.05
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
MONGODB, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2018 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Federal Statutory Rate | 33.80% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | 7.60% | 2.80% | 11.10% |
| Foreign Rate Differential | — | — | — | — |
| Other Adjustments | — | — | — | — |
| R&D Tax Credits | — | -24.10% | -33.90% | -51.30% |
| SBC (Nondeductible) | — | 39.60% | -1.30% | 0.80% |
| Effective Tax Rate | — | -8.00% | 1.90% | -27.80% |
Cash vs Accrual
| Item | FY2018 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Income Tax Expense (Accrual) | $1.3M | $13.1M | −$2.5M | $15.5M |
| Income Taxes Paid (Cash) | $1.0M | $13.6M | $14.6M | $14.5M |
MONGODB, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.